Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | ICMT | O60725 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1009427 | 0.89 | ICMT (0.42) | TBXA2RPTGDRPTGDR2EPHX1EPHX2 | |
| SCHEMBL8738079 | 0.87 | PTGDR2 (0.40) | TBXA2RPTGDRPTGDR2EPHX1EPHX2 | |
| SCHEMBL1009806 | 0.87 | TBXA2R (0.39) | TBXA2RPTGDRPTGDR2EPHX2POLB | |
| SCHEMBL8738226 | 0.86 | PTGDR2 (0.44) | TBXA2RPTGDRPTGDR2EPHX2POLB | |
| SCHEMBL3443109 | 0.84 | POLB (0.39) | TBXA2RPTGDRPTGDR2EPHX1EPHX2 | |
| SCHEMBL8738677 | 0.84 | PTGDR2 (0.44) | TBXA2RPTGDRPTGDR2EPHX2POLB | |
| SCHEMBL8737850 | 0.84 | PTGDR2 (0.43) | TBXA2RPTGDRPTGDR2EPHX1EPHX2 | |
| SCHEMBL2003191 | 0.84 | TBXA2R (0.43) | TBXA2RPTGDRPTGDR2EPHX1EPHX2 | |
| SCHEMBL8737660 | 0.83 | FFAR1 (0.40) | TBXA2RPTGDRPTGDR2EPHX2ALDH1A1 | |
| SCHEMBL1652083 | 0.83 | KMT2A (0.43) | TBXA2RPTGDRPTGDR2EPHX1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129820-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129820-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| US-7960393-B2 | Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 | ACTIMIS PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960393-B2 | Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 | ACTIMIS PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100322980-A1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 | GB005, INC. | 2010-12-23 | — | — | US | disclosed |
| US-20100322980-A1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 | GB005, INC. | 2010-12-23 | — | — | US | disclosed |
| US-7812160-B2 | Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 | ACTIMIS PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812160-B2 | Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 | ACTIMIS PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070129355-A1 | G-protein-coupled chemoattractant receptor, expressed on T helper cells antagonists such as [4-(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)-5-pyrimidinyl]acetic acid;, used for the treatment of allergic diseases, inflammatory diseases, eosinophil- and basophil-related diseases | ACTIMIS PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | US | disclosed |
| US-20070129355-A1 | G-protein-coupled chemoattractant receptor, expressed on T helper cells antagonists such as [4-(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)-5-pyrimidinyl]acetic acid;, used for the treatment of allergic diseases, inflammatory diseases, eosinophil- and basophil-related diseases | ACTIMIS PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129355-A1 | G-protein-coupled chemoattractant receptor, expressed on T helper cells antagonists such as [4-(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)-5-pyrimidinyl]acetic acid;, used for the treatment of allergic diseases, inflammatory diseases, eosinophil- and basophil-related diseases | HRH2, HRH1, HRH4 | TBXA2R 48/4885PTGDR 81/4885PTGDR2 78/4885 |
| US-20100322980-A1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 | HRH2, HRH1, CXCR2 | TBXA2R 60/4885PTGDR 111/4885PTGDR2 73/4885 |
| US-20120129820-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | HRH2, HRH1, HRH4 | TBXA2R 20/4885PTGDR 30/4885PTGDR2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.